Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries

Yock Young Dan, John B. Wong, Saeed S. Hamid, Kwang Hyub Han, Ji Dong Jia, Chun Jen Liu, Teerha Piratvisuth, Anna S.F. Lok, Seng Gee Lim

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Purpose: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party to develop a consensus cost-effectiveness model for treatment of Hepatitis B in Asia Pacific countries in March 2010. Methods: The working party consisted of expert hepatologists, virologists and epidemiologists from 11 representative countries in the Asia Pacific region. Meetings were conducted at the 20th APASL Annual Meeting in 2010 to determine consensus estimates for modeling and at the 21st and 22nd APASL meetings in 2011 and 2012, respectively to review and approve the models. Results: The consensus cost-effectiveness model used Singapore as base case analysis and was validated using actual data from the Singapore Cancer, Diseases and Death Registries. Simulation for Singapore, China, Thailand, Pakistan, Taiwan and Korea were performed. Antivirals with high resistance barriers like entecavir and tenofovir had the highest retail cost but were the most cost-effective therapy in developed countries such as Singapore, Taiwan and Korea while generic tenofovir was most cost effective in Thailand and Pakistan. The cost effectiveness of different treatment strategies varied significantly between countries and was affected by medication cost, economic affordability, access to liver transplantation and the prevailing health of the general population. Conclusion: Choosing treatment strategies for hepatitis B based on low retail drug cost can be misleading because more expensive drugs may be more cost effective when considering long-term health outcomes and costs. Cost-effectiveness data should be individualized to countries based on their unique socio-economic conditions. Governmental policies which subsidize more costly drugs that have lower risk of drug resistance can benefit more patients.

Original languageEnglish
Pages (from-to)382-394
Number of pages13
JournalHepatology International
Volume8
Issue number3
DOIs
Publication statusPublished - 2014 Jul

Bibliographical note

Funding Information:
article does not contain any studies with human or animal subjects. Dr. Dan Yock Young has received speaker honorariums and consultancy fees from Novartis, GSK, Gilead, Bristol Myers Squibb, MSD, Sanofi-Aventis and Roche. Dr. Kwang Hyub Han has received research grants and speaker honorarium from Sanofi Aventis. Dr. Ji Dong Jia has received speaker honorariums and consultancy fees from Novartis, Gilead, Bristol Myers Squibb, MSD, Boehringer Ingelheim and Roche. Dr. Chun Jen Liu has received speaker honorarium from Gilead, Bristol Myers Squibb, MSD and Roche. Dr. Teerha Piratvisuth has received research grants, speaker honorarium, and consultancy fees from Novartis, GSK, Bristol Myers Squibb, MSD and Roche. Dr. ASF Lok has served on advisory boards of Gilead, GlaxoSmithKline and Merck and has received research grants from Bristol-Myers Squibb, Gilead and Merck. Dr. Seng Gee Lim has received speaker honorariums and consultancy fees from Novartis, GSK, Gilead, Bristol Myers Squibb, MSD and Roche. Dr. Saeed Hamid and Dr JB Wong do not have any conflict of interest.

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries'. Together they form a unique fingerprint.

Cite this